© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Converge Coverage
Uptake of new heart failure drugs slow despite guidelines
EXPERT ANALYSIS FROM THE CARDIOVASCULAR CONFERENCE AT SNOWMASS
Related Articles
Coding Corner: Talk the Talk, Bill the Bill: Navigating Advance Care Discussion Billing
April 5, 2017
A 75-year-old woman with a previous medical history of high blood pressure, diabetes mellitus, stage 4 chronic kidney disease, and lung cancer was admitted to the hospital with chest pain and...
Empagliflozin After Acute Myocardial Infarction (EMPACT-MI)
April 5, 2017
Clinical question: Does starting empagliflozin for patients with acute myocardial infarction (AMI) and new onset systolic heart failure (HF) or congestive symptoms reduce the risk of first...
Higher Rates of Major Hemorrhage with Rivaroxaban and Warfarin
April 5, 2017
Clinical question: How effective and safe are apixaban versus rivaroxaban versus warfarin in patients with cirrhosis and nonvalvular atrial fibrillation (AF)? Background: Apixaban, rivaroxaban, and...
Detectable MNPs in Carotid Artery Plaques Are Associated with a Higher Risk of Myocardial Infarction, Stroke, or Death
April 5, 2017
Clinical question: Do patients with carotid artery plaque containing detectable microplastics and nanoplastics (MNPs) have a higher risk of myocardial infarction, stroke, or death? Background:...